# TriClip

Product · id `cardio:triclip` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: TriClip G4; TriClip Device

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A device from Abbott for a leaky tricuspid valve (tricuspid regurgitation). It is delivered through a catheter and is a form of transcatheter edge-to-edge repair. The US FDA approved the TriClip G4 System in 2024 to improve quality of life and daily function in people with symptomatic severe tricuspid regurgitation who are at intermediate or greater risk for surgery. The TRILUMINATE trial tested it.

## Technical summary

TriClip G4 System, FDA product code NPS, PMA P230007, approved 2024-04-01. The FDA indication is improving quality of life and functional status, not survival or hospitalization. TRILUMINATE Pivotal registry NCT03904147 names the intervention TriClip Device. The atlas has no separate tricuspid regurgitation record, so the trial claim files under heart valve disease. Later supplements are not read here.

## Claims, with the population each applies to

## Context: United States PMA approval P230007: TriClip G4 for severe tricuspid regurgitation

Recipient: Recipient not specified; Population: Patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, at intermediate or greater risk for surgery, in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team. The order gives no age range.; Care setting: Multidisciplinary heart team (order wording); Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### On 2024-04-01 the US Food and Drug Administration approved the TriClip G4 System under PMA P230007, product code NPS, applicant ABBOTT MEDICAL. The approval order states the use as improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, at intermediate or greater risk for surgery, in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team. The order gives no age range.; Care setting: Multidisciplinary heart team (order wording); Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: openFDA copies the approval order statement and may lose characters; where a symbol is missing it is not restored here. The FDA PMA database page, the approval order and the summary of safety and effectiveness were not read, so conditions of approval and trial results are not recorded. An approval is a regulatory decision and not a finding about how well the device works for any person. openFDA's own disclaimer says not to rely on it to make decisions regarding medical care. The stated purpose is quality of life and functional status.
- Last checked: 2026-10-14
- Sources:
  1. Supports: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: results\[0\].pma\_number. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: The PMA number of this record.
  2. Supports: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: results\[0\].applicant. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: The applicant, as FDA writes the name.
  3. Supports: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: results\[0\].trade\_name. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: The trade name FDA gives this record.
  4. Supports: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: results\[0\].decision\_date. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: ISO date of the decision.
  5. Supports: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: results\[0\].decision\_code. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: FDA decision code: APPR is an approval.
  6. Supports: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: results\[0\].product\_code. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: FDA product code of this record.
  7. Supports: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: results\[0\].ao\_statement. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: FDA approval order statement: the approved indication, quoted in fragments.
  8. Background: FDA premarket approval record P230007: TriClip G4 System (original PMA approval) (openFDA record) (Regulator, edition The openFDA PMA record returned on 2026-10-14 for P230007 (the earliest record by decision date, which is the original approval, with no supplement number), from a dataset last updated 2026-10-05. The FDA PMA database page was not fetched for this record.) <https://api.fda.gov/device/pma.json?search=pma_number:P230007&sort=decision_date:asc&limit=1>
     Locator: meta.disclaimer. Retrieved 2026-10-14T18:21:11Z. Source state: Current. Snapshot hash: d7355536c1d998032d89adf47081e9fd56d2ec3e93227d518567af13bbd5e071.
     How it applies: openFDA's own disclaimer about relying on its data.

## Context: Adults with symptomatic severe tricuspid regurgitation, randomized in TRILUMINATE Pivotal

Recipient: Adult; Population: Patients 18 years or older (registry minimum age) with symptomatic severe tricuspid regurgitation, 350 of whom were randomized 1:1 at 65 centers in the United States, Canada and Europe (175 to each group). The abstract gives a mean age of 78 years, with 54.9% women. The registry record also covers a single-arm cohort and a continued access study. The detailed inclusion and exclusion criteria are in the registry record and were not extracted.; Care setting: 65 centers in the United States, Canada and Europe (abstract); Geography: United States, Canada and Europe; Life stage: Registry minimum age 18 years; mean age 78 years (abstract); Follow-up: The primary end point was at 12 months (abstract). The registry gives the primary completion as 2022-11-18 and an estimated study completion of 2029-04.

### In TRILUMINATE Pivotal, 350 patients with symptomatic severe tricuspid regurgitation were randomized 1:1 at 65 centers to transcatheter edge-to-edge repair (the TriClip device) plus medical therapy or to medical therapy alone (175 patients in each group). The primary end point was a hierarchical composite of death from any cause or tricuspid-valve surgery, hospitalization for heart failure, and an improvement of at least 15 points on the Kansas City Cardiomyopathy Questionnaire (a quality-of-life score) at 1 year. The result favored repair (win ratio 1.48, 95% confidence interval 1.06 to 2.13, P = 0.02). The incidence of death or tricuspid-valve surgery and the rate of hospitalization for heart failure did not appear to differ between the groups. The quality-of-life score changed by 12.3 points with repair and 0.6 points in the control group. At 30 days, 87.0% of the repair group and 4.8% of the control group had tricuspid regurgitation of no greater than moderate severity. 98.3% of the patients who had the procedure were free from major adverse events at 30 days.

- Category: Effect
- Evidence stage: Interventional
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Patients 18 years or older (registry minimum age) with symptomatic severe tricuspid regurgitation, 350 of whom were randomized 1:1 at 65 centers in the United States, Canada and Europe (175 to each group). The abstract gives a mean age of 78 years, with 54.9% women. The registry record also covers a single-arm cohort and a continued access study. The detailed inclusion and exclusion criteria are in the registry record and were not extracted.; Care setting: 65 centers in the United States, Canada and Europe (abstract); Geography: United States, Canada and Europe; Life stage: Registry minimum age 18 years; mean age 78 years (abstract); Follow-up: The primary end point was at 12 months (abstract). The registry gives the primary completion as 2022-11-18 and an estimated study completion of 2029-04.
- Limitations: Funded by Abbott; the registry lists Abbott Medical Devices as lead sponsor and FDA lists ABBOTT MEDICAL as applicant for the device. The registry records masking of the outcomes assessor only. The abstract reports no apparent difference in death or tricuspid-valve surgery, or in hospitalization for heart failure, so the benefit shown is in the combined score, in quality of life and in the severity of the regurgitation. The abstract does not say how much each component contributed to the win ratio. The FDA indication is for quality of life and function, not for survival or hospitalization. The result is at 1 year. Only the abstract was read.
- Last checked: 2026-10-14
- Sources:
  1. Supports: Transcatheter Repair for Patients with Tricuspid Regurgitation (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities, fetched 2026-10-14. PubMed lists no PMC copy. The version of record was not fetched: the NEJM page returned HTTP 403 (a bot challenge page) when tried on 2026-10-14 for the PARTNER 3 paper, and the other NEJM papers were not tried.) <https://doi.org/10.1056/NEJMoa2300525>
     Locator: Abstract, RESULTS, sentence 3. Retrieved 2026-10-14T18:18:30Z. Source state: Current. Snapshot hash: 4bcb9a0f855b7342a6e3a38e0b97f7d9b7cb3d693100165b1d95b2b5318dfc9e.
     How it applies: The primary end point result, as a win ratio.
  2. Opposes: Transcatheter Repair for Patients with Tricuspid Regurgitation (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities, fetched 2026-10-14. PubMed lists no PMC copy. The version of record was not fetched: the NEJM page returned HTTP 403 (a bot challenge page) when tried on 2026-10-14 for the PARTNER 3 paper, and the other NEJM papers were not tried.) <https://doi.org/10.1056/NEJMoa2300525>
     Locator: Abstract, RESULTS, sentence 4. Retrieved 2026-10-14T18:18:30Z. Source state: Current. Snapshot hash: 4bcb9a0f855b7342a6e3a38e0b97f7d9b7cb3d693100165b1d95b2b5318dfc9e.
     How it applies: Death or tricuspid-valve surgery and heart-failure hospitalization did not appear to differ.
  3. Supports: Transcatheter Repair for Patients with Tricuspid Regurgitation (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities, fetched 2026-10-14. PubMed lists no PMC copy. The version of record was not fetched: the NEJM page returned HTTP 403 (a bot challenge page) when tried on 2026-10-14 for the PARTNER 3 paper, and the other NEJM papers were not tried.) <https://doi.org/10.1056/NEJMoa2300525>
     Locator: Abstract, RESULTS, sentences 5 to 7. Retrieved 2026-10-14T18:18:30Z. Source state: Current. Snapshot hash: 4bcb9a0f855b7342a6e3a38e0b97f7d9b7cb3d693100165b1d95b2b5318dfc9e.
     How it applies: Quality-of-life change, regurgitation at 30 days and 30-day safety.
  4. Background: Transcatheter Repair for Patients with Tricuspid Regurgitation (Publication, edition PubMed record (abstract and bibliographic data) from NCBI E-utilities, fetched 2026-10-14. PubMed lists no PMC copy. The version of record was not fetched: the NEJM page returned HTTP 403 (a bot challenge page) when tried on 2026-10-14 for the PARTNER 3 paper, and the other NEJM papers were not tried.) <https://doi.org/10.1056/NEJMoa2300525>
     Locator: Abstract, METHODS, sentences 1 to 3. Retrieved 2026-10-14T18:18:30Z. Source state: Current. Snapshot hash: 4bcb9a0f855b7342a6e3a38e0b97f7d9b7cb3d693100165b1d95b2b5318dfc9e.
     How it applies: Design, sites and the definition of the primary end point.
  5. Background: TRILUMINATE Pivotal Trial (Registry, edition ClinicalTrials.gov API v2 record, last update posted 2024-12-19.) <https://clinicaltrials.gov/study/NCT03904147>
     Locator: protocolSection.designModule.designInfo.maskingInfo.whoMasked\[0\]. Retrieved 2026-10-14T18:18:28Z. Source state: Current. Snapshot hash: eaffdf5982436716f80e451c85f426687ddb1535fd6ddd11c41dd6677f9c7255.
     How it applies: The registry records the outcomes assessor as the one masked party.
  6. Background: TRILUMINATE Pivotal Trial (Registry, edition ClinicalTrials.gov API v2 record, last update posted 2024-12-19.) <https://clinicaltrials.gov/study/NCT03904147>
     Locator: protocolSection.armsInterventionsModule.armGroups\[0\].description. Retrieved 2026-10-14T18:18:28Z. Source state: Current. Snapshot hash: eaffdf5982436716f80e451c85f426687ddb1535fd6ddd11c41dd6677f9c7255.
     How it applies: Registry description of the device group: TriClip implantation with continued medical therapy.
  7. Background: TRILUMINATE Pivotal Trial (Registry, edition ClinicalTrials.gov API v2 record, last update posted 2024-12-19.) <https://clinicaltrials.gov/study/NCT03904147>
     Locator: protocolSection.armsInterventionsModule.armGroups\[1\].description. Retrieved 2026-10-14T18:18:28Z. Source state: Current. Snapshot hash: eaffdf5982436716f80e451c85f426687ddb1535fd6ddd11c41dd6677f9c7255.
     How it applies: Registry description of the control group: continued medical therapy.

## Guidance, authorization and access

### Regulatory decision `cardio:regdec-fda-p230007`

- Product: TriClip (`cardio:triclip`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Approval, 2024-04-01
- Product version: TriClip G4 System (original approval)
- Pathway: PMA
- Submission: P230007
- Product code: NPS
- Device class: III
- Indication: Improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, at intermediate or greater risk for surgery, in whom transcatheter edge-to-edge repair is clinically appropriate and expected to reduce regurgitation severity to moderate or less.
- Jurisdictions: United States; note: United States
- Applies to: Recipient: Recipient not specified; Population: Patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, at intermediate or greater risk for surgery, in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team. The order gives no age range.; Care setting: Multidisciplinary heart team (order wording); Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:claim-fda-p230007-approval`

## Connected pages

- Applicant on P230007 is ABBOTT MEDICAL; the sources read do not say who makes the device: Abbott (`cardio:abbott`)
- A transcatheter edge-to-edge repair device: Transcatheter edge-to-edge repair (TEER) (`cardio:transcatheter-edge-to-edge-repair`)
- TRILUMINATE Pivotal, severe tricuspid regurgitation: better combined result for the clip plus medicines, but no apparent difference in death, surgery or heart-failure hospitalization: Heart valve disease (`cardio:heart-valve-disease`) [a claim, not a settled fact; see claim `cardio:claim-triluminate-primary` and its context]
- Filed under this front: Procedures and surgery (`cardio:front-procedures-and-surgery`)
- Investigated in: TRILUMINATE Pivotal trial (`cardio:triluminate`)

## Provenance

Content hash: b28f07dfdacba5f806cafdba45ad197ca78a74e5100d180ca1f32ed28c0d66c7
Last substantive edit: 2026-10-14
Evidence last checked: 2026-10-14